As of 2026-05-09, the Intrinsic Value of Lotus Pharmaceuticals Inc (LTUS) is 5.55 USD. This LTUS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 0.00 USD, the upside of Lotus Pharmaceuticals Inc is 154,101.20%.
The range of the Intrinsic Value is 4.56 - 7.15 USD
Based on its market price of 0.00 USD and our intrinsic valuation, Lotus Pharmaceuticals Inc (LTUS) is undervalued by 154,101.20%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 4.56 - 7.15 | 5.55 | 154101.2% |
| DCF (Growth 10y) | 6.82 - 10.61 | 8.28 | 229882.6% |
| DCF (EBITDA 5y) | 8.62 - 12.65 | 10.66 | 296039.4% |
| DCF (EBITDA 10y) | 10.08 - 14.98 | 12.49 | 346714.3% |
| Fair Value | 1.56 - 1.56 | 1.56 | 43,240.97% |
| P/E | 0.33 - 7.30 | 3.84 | 106575.5% |
| EV/EBITDA | 3.87 - 17.43 | 10.10 | 280331.4% |
| EPV | 1.69 - 2.19 | 1.94 | 53828.5% |
| DDM - Stable | 0.03 - 0.09 | 0.06 | 1677.6% |
| DDM - Multi | 0.06 - 0.22 | 0.10 | 2779.5% |
| Market Cap (mil) | 0.10 |
| Beta | 0.27 |
| Outstanding shares (mil) | 27.82 |
| Enterprise Value (mil) | 5.36 |
| Market risk premium | 4.60% |
| Cost of Equity | 95.56% |
| Cost of Debt | 5.00% |
| WACC | 5.39% |